Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Immuneonco Biopharmaceuticals (Shanghai) Receives FDA Approval For IND Application ...

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Immuneonco Biopharmaceuticals (Shanghai) has received FDA approval for the IND application of IMM0306 to begin a Phase 1B/2 trial for systemic lupus erythematosus (SLE), enabling clinical development in the US market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech venture just gained market entry potential in the US with FDA clearance for a Phase 1B/2 trial. Prioritise building US clinical partnerships and supply chains to capitalise on this regulatory green light.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalclinical-trialimmunotherapybiopharmaus-market